CS195269B2 - Method of producing novel derivatives of triazolobenzodiazepine - Google Patents
Method of producing novel derivatives of triazolobenzodiazepine Download PDFInfo
- Publication number
- CS195269B2 CS195269B2 CS741158A CS115874A CS195269B2 CS 195269 B2 CS195269 B2 CS 195269B2 CS 741158 A CS741158 A CS 741158A CS 115874 A CS115874 A CS 115874A CS 195269 B2 CS195269 B2 CS 195269B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- compound
- chloromethyl
- reaction
- chloro
- triazole
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- KYTREVLPRJOBEM-UHFFFAOYSA-N triazolo[4,5-i][1,2]benzodiazepine Chemical class C1=CC2=CC=CN=NC2=C2C1=NN=N2 KYTREVLPRJOBEM-UHFFFAOYSA-N 0.000 title claims description 5
- -1 alkoxy radicals Chemical class 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000005977 Ethylene Substances 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims abstract 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940102253 isopropanolamine Drugs 0.000 claims description 2
- PAUGTBXMNTXAMM-UHFFFAOYSA-N morpholin-3-ylidenemethanone Chemical compound O=C=C1COCCN1 PAUGTBXMNTXAMM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- FTOVKFVJDIQHIM-UHFFFAOYSA-N (4-methylpiperazin-2-ylidene)methanone Chemical compound CN1CCNC(=C=O)C1 FTOVKFVJDIQHIM-UHFFFAOYSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- UUZQLJWNLUFVAE-UHFFFAOYSA-N 1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-5-(chloromethyl)-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=C(CCl)N1C1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1Cl UUZQLJWNLUFVAE-UHFFFAOYSA-N 0.000 claims 1
- CJYHJHPYTWFLHS-UHFFFAOYSA-N 1h-1,4-benzodiazepine-2-carboxamide Chemical compound N1C(C(=O)N)=CN=CC2=CC=CC=C21 CJYHJHPYTWFLHS-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- PULBONHWNLERMR-UHFFFAOYSA-N 6h-1,2-benzodiazepine-7-carboxamide Chemical compound N1=NC=CC=C2CC(C(=O)N)=CC=C21 PULBONHWNLERMR-UHFFFAOYSA-N 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 150000001408 amides Chemical class 0.000 abstract description 5
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 abstract description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052794 bromium Inorganic materials 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000932 sedative agent Substances 0.000 abstract description 3
- 230000001624 sedative effect Effects 0.000 abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 229910052801 chlorine Inorganic materials 0.000 abstract description 2
- 229910052731 fluorine Inorganic materials 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract description 2
- 150000002367 halogens Chemical group 0.000 abstract description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 4
- 150000001412 amines Chemical class 0.000 abstract 4
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 abstract 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 abstract 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 2
- 229910021529 ammonia Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 abstract 1
- WBBZFWQDOPAVCJ-UHFFFAOYSA-N 2-chloro-2-hydrazinylideneacetic acid Chemical class NN=C(Cl)C(O)=O WBBZFWQDOPAVCJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 230000002082 anti-convulsion Effects 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000006193 diazotization reaction Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 95
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 62
- 235000019441 ethanol Nutrition 0.000 description 49
- 238000001953 recrystallisation Methods 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 5
- 150000001557 benzodiazepines Chemical class 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- MJAXYZXQWWPJTF-UHFFFAOYSA-N ethyl 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-1,2,4-triazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)N=C(CCl)N1C1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 MJAXYZXQWWPJTF-UHFFFAOYSA-N 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ZUWXHHBROGLWNH-UHFFFAOYSA-N (2-amino-5-chlorophenyl)-phenylmethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 ZUWXHHBROGLWNH-UHFFFAOYSA-N 0.000 description 1
- ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical compound NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 description 1
- RZMGZEJEAAVXRG-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxylic acid Chemical compound N1NN(C=C1)C(=O)O RZMGZEJEAAVXRG-UHFFFAOYSA-N 0.000 description 1
- SOYOCBJBBPMAQW-UHFFFAOYSA-N 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=C(CCl)N1C1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 SOYOCBJBBPMAQW-UHFFFAOYSA-N 0.000 description 1
- BDMLDWKLIAIPFN-UHFFFAOYSA-N 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-1,2,4-triazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)N=C(CCl)N1C1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 BDMLDWKLIAIPFN-UHFFFAOYSA-N 0.000 description 1
- SXXRGIXHBFYDQN-UHFFFAOYSA-N 1-(2-benzoyl-4-methylphenyl)-5-(chloromethyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C(C)=CC=C(N2C(=NC(=N2)C(O)=O)CCl)C=1C(=O)C1=CC=CC=C1 SXXRGIXHBFYDQN-UHFFFAOYSA-N 0.000 description 1
- SRTPNFFWJQVKKZ-UHFFFAOYSA-N 1-(2-benzyl-4-methylphenyl)-5-(chloromethyl)-1,2,4-triazole-3-carboxamide Chemical compound C(C1=CC=CC=C1)C1=C(C=CC(=C1)C)N1N=C(N=C1CCl)C(=O)N SRTPNFFWJQVKKZ-UHFFFAOYSA-N 0.000 description 1
- CXSQNRLNVWMBIR-UHFFFAOYSA-N 1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-5-(chloromethyl)-1,2,4-triazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)N=C(CCl)N1C1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1Cl CXSQNRLNVWMBIR-UHFFFAOYSA-N 0.000 description 1
- LIUSZSAPZUPWNO-UHFFFAOYSA-N 1-[4-chloro-2-(4-methoxybenzoyl)phenyl]-5-(chloromethyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC(Cl)=CC=C1N1C(CCl)=NC(C(O)=O)=N1 LIUSZSAPZUPWNO-UHFFFAOYSA-N 0.000 description 1
- IJLDEWIREJQNIV-UHFFFAOYSA-N 15-chloro-12-(2-chlorophenyl)-11-oxa-2,3,5,8-tetrazatetracyclo[11.4.0.02,6.08,12]heptadeca-1(13),3,5,14,16-pentaene-4-carboxamide Chemical compound C12=CC(Cl)=CC=C2N2N=C(C(=O)N)N=C2CN2CCOC21C1=CC=CC=C1Cl IJLDEWIREJQNIV-UHFFFAOYSA-N 0.000 description 1
- LJVQHXICFCZRJN-UHFFFAOYSA-N 1h-1,2,4-triazole-5-carboxylic acid Chemical compound OC(=O)C1=NC=NN1 LJVQHXICFCZRJN-UHFFFAOYSA-N 0.000 description 1
- TUTKZBLQYOHHJH-UHFFFAOYSA-N 2-(2-benzoylphenyl)-5-(chloromethyl)-1h-1,2,4-triazole-5-carboxylic acid Chemical compound C1=NC(C(=O)O)(CCl)NN1C1=CC=CC=C1C(=O)C1=CC=CC=C1 TUTKZBLQYOHHJH-UHFFFAOYSA-N 0.000 description 1
- DLDTUYIGYMNERN-UHFFFAOYSA-N 2-[(2-chloroacetyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)CCl DLDTUYIGYMNERN-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WRQAHWMWYQDKGD-UHFFFAOYSA-N 6h-1,4-benzodiazepine-7-carboxamide Chemical compound N1=CC=NC=C2CC(C(=O)N)=CC=C21 WRQAHWMWYQDKGD-UHFFFAOYSA-N 0.000 description 1
- YFSKPTLFKHGIGT-UHFFFAOYSA-N 6h-1,4-benzodiazepine-7-carboxylic acid Chemical compound N1=CC=NC=C2CC(C(=O)O)=CC=C21 YFSKPTLFKHGIGT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- BVIXDZIQDYXWQL-UHFFFAOYSA-N azane;morpholine Chemical compound N.C1COCCN1 BVIXDZIQDYXWQL-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical class ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- XXQQUDQARDWTAK-UHFFFAOYSA-N ethyl 1-(2-benzoyl-4-methylphenyl)-5-(chloromethyl)-1,2,4-triazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)N=C(CCl)N1C1=CC=C(C)C=C1C(=O)C1=CC=CC=C1 XXQQUDQARDWTAK-UHFFFAOYSA-N 0.000 description 1
- RIIVGZNBOBCPKS-UHFFFAOYSA-N ethyl 2-[(2-benzoyl-4-chlorophenyl)diazenyl]-2-[(2-chloroacetyl)amino]acetate Chemical compound CCOC(=O)C(NC(=O)CCl)N=NC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 RIIVGZNBOBCPKS-UHFFFAOYSA-N 0.000 description 1
- RYRALQYIMXDQBX-UHFFFAOYSA-N ethyl 2-[(2-benzoylphenyl)diazenyl]-2-chloroacetate Chemical compound CCOC(=O)C(Cl)N=NC1=CC=CC=C1C(=O)C1=CC=CC=C1 RYRALQYIMXDQBX-UHFFFAOYSA-N 0.000 description 1
- PQWDDWRCEARMMC-UHFFFAOYSA-N ethyl 2-amino-2-[(2-benzoyl-4-chlorophenyl)diazenyl]acetate Chemical compound CCOC(=O)C(N)N=NC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 PQWDDWRCEARMMC-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910001511 metal iodide Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- SHCXEQQBQRQPKY-UHFFFAOYSA-N n,n-dimethyl-1h-1,2,4-triazole-5-carboxamide Chemical compound CN(C)C(=O)C=1N=CNN=1 SHCXEQQBQRQPKY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000008023 pharmaceutical filler Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP48019930A JPS5750797B2 (hu) | 1973-02-19 | 1973-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CS195269B2 true CS195269B2 (en) | 1980-01-31 |
Family
ID=12012923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS741158A CS195269B2 (en) | 1973-02-19 | 1974-02-18 | Method of producing novel derivatives of triazolobenzodiazepine |
Country Status (15)
Country | Link |
---|---|
US (1) | US3947417A (hu) |
JP (1) | JPS5750797B2 (hu) |
AT (1) | AT336623B (hu) |
BE (1) | BE811199A (hu) |
CA (1) | CA1043783A (hu) |
CH (1) | CH594678A5 (hu) |
CS (1) | CS195269B2 (hu) |
DE (1) | DE2407731A1 (hu) |
DK (1) | DK141727B (hu) |
FI (1) | FI56385C (hu) |
FR (1) | FR2218339B1 (hu) |
GB (1) | GB1424305A (hu) |
HU (1) | HU168871B (hu) |
NL (1) | NL7402220A (hu) |
SE (1) | SE414498B (hu) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6156516A (ja) * | 1984-07-23 | 1986-03-22 | Nok Corp | アナログ・デジタル変換装置 |
US4596799A (en) * | 1985-01-29 | 1986-06-24 | Ciba-Geigy Corporation | 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755300A (en) * | 1968-10-24 | 1973-08-28 | Sankyo Co | Process for the preparation of benzodiazepine compounds |
US3701782A (en) * | 1972-02-10 | 1972-10-31 | Upjohn Co | 1-carbolower alkoxy - 6 - phenyl-4h-s-triazolo(1,4)benzodiazepine compounds |
-
1973
- 1973-02-19 JP JP48019930A patent/JPS5750797B2/ja not_active Expired
-
1974
- 1974-02-15 CA CA192,697A patent/CA1043783A/en not_active Expired
- 1974-02-15 DK DK79874AA patent/DK141727B/da unknown
- 1974-02-15 AT AT122274A patent/AT336623B/de not_active IP Right Cessation
- 1974-02-18 HU HUTA1291A patent/HU168871B/hu unknown
- 1974-02-18 BE BE141064A patent/BE811199A/xx unknown
- 1974-02-18 DE DE19742407731 patent/DE2407731A1/de not_active Withdrawn
- 1974-02-18 NL NL7402220A patent/NL7402220A/xx not_active Application Discontinuation
- 1974-02-18 CS CS741158A patent/CS195269B2/cs unknown
- 1974-02-18 SE SE7402119A patent/SE414498B/xx unknown
- 1974-02-18 FR FR7405424A patent/FR2218339B1/fr not_active Expired
- 1974-02-19 CH CH230474A patent/CH594678A5/xx not_active IP Right Cessation
- 1974-02-19 FI FI476/74A patent/FI56385C/fi active
- 1974-02-19 US US05/443,528 patent/US3947417A/en not_active Expired - Lifetime
- 1974-02-19 GB GB747974A patent/GB1424305A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FI56385B (fi) | 1979-09-28 |
SE414498B (sv) | 1980-08-04 |
FR2218339B1 (hu) | 1980-01-18 |
CA1043783A (en) | 1978-12-05 |
CH594678A5 (hu) | 1978-01-13 |
DE2407731A1 (de) | 1974-08-22 |
ATA122274A (de) | 1976-09-15 |
AT336623B (de) | 1977-05-10 |
AU6554974A (en) | 1975-08-14 |
JPS49108099A (hu) | 1974-10-14 |
DK141727B (da) | 1980-06-02 |
JPS5750797B2 (hu) | 1982-10-28 |
HU168871B (hu) | 1976-07-28 |
FI56385C (fi) | 1980-01-10 |
FR2218339A1 (hu) | 1974-09-13 |
GB1424305A (en) | 1976-02-11 |
US3947417A (en) | 1976-03-30 |
DK141727C (hu) | 1980-10-27 |
NL7402220A (hu) | 1974-08-21 |
BE811199A (fr) | 1974-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE28505E (en) | -phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines | |
US4795749A (en) | Imidazopyrroloquinoxaline compounds | |
US4622320A (en) | Oxadiazolylimidazobenzodiazepine, compositions, and method | |
NO873108L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 1,4-benzodiazepiner. | |
DE2262653A1 (de) | Neue 7-substituierte 3,5-dihydro-astriazino- eckige klammer auf 4,3-a eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepine, deren 6-oxyde und verfahren zu ihrer herstellung | |
CS195269B2 (en) | Method of producing novel derivatives of triazolobenzodiazepine | |
US3862171A (en) | 6-phenyl-4h-s-triazolo(1,5-a)(1,4)benzodiazepine-2-carboxylic acids and their esters | |
US3891666A (en) | 6-Phenyl-s-triazolo{8 4,3-a{9 {8 1,3,4{9 -benzotriazepines and their preparation | |
US3717654A (en) | 2,5,6,7-tetrahydro-3h-s-triazolo(4,3-d)(1,4)benzodiazepin-3-one compounds and their production | |
US5885986A (en) | Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use as medicaments | |
CA1256865A (en) | Oxadiazolylimidazobenzodiazepine, compositions, and method iii | |
US3862950A (en) | Dibenzo{8 b,f{9 -5-triazolo{8 4,3-a{9 {8 1,4{9 diazepin-3-ones | |
US3969366A (en) | 3[Substituted-2-(methylamino)phenyl]4-[2-oxo-2-(heterocyclic)ethyl]-5-substituted-1,2,4-triazoles | |
US3822259A (en) | 7-phenyl-1h(1,3)-oxazino(3,2-a)(1,4)benzodiazepine-1,3(2h)-diones | |
US4016165A (en) | Triazino benzodiazepines | |
CS41991A3 (en) | 2,4,8-trisubstituted-3h,6h-1,4,5a,8a-tetraazaacenaphthylene-3,5-(4h)-diones and,4,8-trisubstituted-4,5-dihydro-5-thioxo-3h,6h,1,4,5a, 8a-tetraazaacenaphthylene-3-ons | |
US3714178A (en) | 6,7-DIHYDRO-7-ALKYL-5H-1,2,4-TRIAZOLO[4,3-d][1,4]BENZODIAZEPINES AND THEIR PRODUCTION | |
US3749733A (en) | 4-(2-benzoylphenyl)-2,4-dihydro-5((alkylamino)alkyl)-3h-1,2,4-triazol-3-ones and process | |
US4305952A (en) | 8-Aryl-5,6,7,8-tetrahydropyrazolo(3,4-B)(1,4)-diazepine-1H, 4H-5,7-diones, and medicaments containing these | |
US4075202A (en) | S-triazolo-1,5-benzodiazpine-4-ones | |
EP0202441A1 (en) | Oxadiazolylimidazobenzodiazepines, process for their preparation and pharmaceutical compositions | |
US3880878A (en) | 1-Aminoalkyl-6-phenyl-4H-s-triazolo-{8 4,3-{9 {8 1,3,4{9 benzotriazepines | |
IE53693B1 (en) | Triazolobenzaepines, process and intermediate compounds for their manufacture and medicaments containing them | |
US4831029A (en) | Condensed cyclic triazole derivatives, pharmaceutical compositions and use | |
FI94344C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten triatsolopyrimidiinijohdannaisten valmistamiseksi |